Data reveals mechanisms in our bodies that can help us fight viral pathogenesis.

New apps help researchers with statistical analyses of data.

Scientists have learned more about how drug resistance develops in patients with acute myeloid leukemia and how the process might be slowed.

PNNL is one of the founding partners of the Trillion Parameter Consortium, which was formed to create reliable generative AI models.

PNNL is collaborating with Microsoft, Micron and other partners to make computational chemistry broadly available.

The Rapid Assessment of Platform Technologies to Expedite Response project aims to prepare against future pandemics.

Methods review suggests ways to use artificial intelligence and machine learning to handle missing data when integrating two or more omics approaches.

Gosline works to develop computational algorithms that are uniquely targeted for rare disease work by doing foundational research in model system development. This work can be expanded to all model systems in human disease.

Findings show method to better prepare human lung tissue for study; it represents the latest mass spectrometry-based omics advances.

New research findings published in Science Advances (November 2022), help explain the progression of Alzheimer-related dementia in each patient. The findings outline a biological classification system that predicts disease severity.

The scientist behind the online cartoon RedPen/BlackPen explains how humor can build bridges between scientists and the public.

PNNL scientists are protecting first responders and others by expanding what’s known about fentanyl, the driver of the opioid epidemic.

Scientists have devised a way to engineer yeast to produce sustainable, eco-friendly commodity chemicals using computing power as a guide.

Researchers map nearly 9,000 proteins in the human lungs, providing a clearer picture of development.

The nested nanoPOTS chip is the next generation of technology developed at PNNL to prepare single cells for proteomics.

A study of Middle East Respiratory Syndrome has identified a compound that shows potential in easing the symptoms of coronavirus infections.

PNNL data scientists are refining their artificial intelligence tools with COVID-19 data to advance therapeutics and treatments for a future pandemic.

PNNL researchers are forming a clearer picture of how plant matter is transformed in the microbial gardens created by leaf-cutter ants.

Night shift work disrupts the natural 24-hour rhythms in the activity of certain cancer-related genes, making workers more vulnerable to damage to their DNA.

PNNL computational biologists, structural biologists, and analytical chemists are using their expertise to safely accelerate the design step of the COVID-19 drug discovery process.